TriangleNCT01484314 · OUTCOME
Safety and Tolerability
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- 2 years
What was measured
To determine whether eltrombopag administration results in an increased number of participants with adverse events.
Analysis population: Terminated with 1 patient enrolled; no data due to patient privacy.
Groups in this outcome
Migration Arm
Administration of eltrombopag to support platelets during chemotherapy Eltrombopag: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
| Group | Source count |
|---|---|
| Migration Arm | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- To determine whether eltrombopag administration results in an increased number of participants with adverse events.
- groups
- description
- Administration of eltrombopag to support platelets during chemotherapy Eltrombopag: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
- id
- OG000
- title
- Migration Arm
- population Description
- Terminated with 1 patient enrolled; no data due to patient privacy.
- reporting Status
- POSTED
- time Frame
- 2 years
- title
- Safety and Tolerability
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice